Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/08/19
End: 09/26/24
Due: 09/26/25
Phase: N/A
Priority: Normal
Start: 06/01/22
End: 10/18/23
Due: 10/18/24
Phase: N/A
Priority: Normal
Start: 08/15/19
End: 09/03/24
Due: 09/03/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | NCT04032847 | Achilles Therapeutics UK Limited | user2@example.com | None | 2019-07-08 | 2024-09-26 | 2025-09-26 | - | - | 2025-07-14 |
| Long-Term Follow-Up Study of Patients Receiving ATL001 | NCT04785365 | Achilles Therapeutics UK Limited | user2@example.com | None | 2022-06-01 | 2023-10-18 | 2024-10-18 | - | - | 2025-07-14 |
| ATL001 in Patients With Metastatic or Recurrent Melanoma | NCT03997474 | Achilles Therapeutics UK Limited | user2@example.com | None | 2019-08-15 | 2024-09-03 | 2025-09-03 | - | - | 2025-07-14 |